Finance

Lists
002019:SHE
Yifan Pharmaceutical Co Ltd
CNÂ¥9.59
-0.42%
(-0.040) 1D
Sep 22, 3:04:21 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 002019...
Open
CNÂ¥9.63
High
CNÂ¥9.68
Low
CNÂ¥9.56
Mkt. cap
11.71B
Avg. vol.
12.39M
Volume
6.86M
Dividend
1.04%
Quarterly dividend
CNÂ¥0.03
Ex-dividend date
May 29, 2026
P/E ratio
38.38
52-wk high
CNÂ¥14.73
52-wk low
CNÂ¥9.07
EPS
CNÂ¥0.25
Shares outstanding
1.22B
No. of employees
4K
Open
CNÂ¥9.63
High
CNÂ¥9.68
Low
CNÂ¥9.56
Mkt. cap
11.71B
Avg. vol.
12.39M
Volume
6.86M
Dividend
1.04%
Quarterly dividend
CNÂ¥0.03
Ex-dividend date
May 29, 2026
P/E ratio
38.38
52-wk high
CNÂ¥14.73
52-wk low
CNÂ¥9.07
EPS
CNÂ¥0.25
Shares outstanding
1.22B
No. of employees
4K
About Yifan Pharmaceutical Co Ltd
CEO-
Employees4.18K
Founded1994
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.29B
1.21B
1.26B
1.21B
Cost of goods sold
683.41M
709.78M
680.09M
660.52M
Cost of revenue
683.41M
709.78M
680.09M
660.52M
Research and development expenses
73.24M
99.51M
54.37M
84.82M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
394.37M
380.61M
352.15M
322.47M
Operating expense
414.49M
557.61M
426.93M
417.72M
Total operating expenses
1.10B
1.27B
1.11B
1.08B
Operating income
189.70M
-57.15M
148.49M
133.82M
Other non operating income
4.02M
-9.75M
-9.25M
3.87M
EBT including unusual items
90.49M
-11.11M
120.86M
108.42M
EBT excluding unusual items
171.87M
-75.15M
130.13M
108.62M
Income tax expense
14.39M
-24.31M
25.15M
16.74M
Effective tax rate
15.91%
218.84%
20.81%
15.44%
Other operating expenses
-60.21M
83.25M
11.12M
9.35M
Net income
84.14M
14.23M
106.83M
98.20M
Net profit margin
6.53%
1.18%
8.51%
8.10%
Earnings per share
-
-
-
-
Interest and investment income
2.44M
4.17M
2.64M
2.83M
Interest expense
-16.54M
-10.67M
-11.75M
-11.28M
Net interest expenses
-14.10M
-6.51M
-9.11M
-8.46M
Depreciation and amortization charges
-
-
-
-
EBITDA
268.85M
25.45M
231.09M
220.93M
Gain or loss from assets sale
3.86M
-12.70M
-
1.53M
AI content may include mistakes. Learn more
Google apps